Description

Sarkaria et al identified prognostic classes of high grade malignant gliomas using RTOG (Radiation Therapy Oncology Group) analysis. These can help compare outcomes following therapeutic interventions. The authors are from the University of Wisconsin, Harvard University and the University of Florida at Gainesville.


 

Selection criteria included age > 18 years.

 

Parameter:

(1) type (anaplastic astrocytoma vs glioblastoma multiforme)

(2) age of the patient

(3) mental status

(4) Karnofsky performance scale (KPS)

(5) duration of symptoms before diagnosis

(6) functional status

(7) surgery (partial or total resection vs biopsy)

 

Anaplastic Astrocytoma

 

Parameter

Class 1

Class 2

Class 3

age in years

< 50 years

>= 50 years

< 50 years

mental status

normal

 

abnormal

KPS

 

>= 70

 

duration

 

> 3 months

 

functional status

 

 

 

surgery

 

 

 

 

 

Parameter

Class 4

Class 5

Class 6

age in years

>= 50 years

>= 50 years

>= 50 years

mental status

 

normal

abnormal

KPS

>= 70

< 70

< 70

duration

<= 3 months

 

 

functional status

 

 

 

surgery

 

 

 

 

Glioblastoma Multiforme

 

Parameter

Class 3

Class 4a

Class 4b

age in years

< 50 years

< 50 years

>= 50

mental status

 

 

 

KPS

>= 90

< 90

>= 70

duration

 

 

 

functional status

 

 

working

surgery

 

 

resection

 

 

Parameter

Class 5a

Class 5b

Class 5c

age in years

>= 50

>= 50

>= 50

mental status

 

 

normal

KPS

>= 70

>= 70

< 70

duration

 

 

 

functional status

not working

 

 

surgery

resection

biopsy

 

 

 

Parameter

Class 6

age in years

>= 50 years

mental status

abnormal

KPS

< 70

duration

 

functional status

 

surgery

 

 

Patients were treated with surgery, external beam radiation and linac-based radiosurgery.

 

Prognostic classes 1, 2 and 3 had a relatively favorable outcome with survival at 2 years from 75-81% (75% at 3 years for 1 and 2, 45% at 3 years for group 3).

 

Prognostic classes 4, 5 and 6 had a relatively unfavorable outcome with survival at 2 years from 21-34% (< 10% at 3 years).

 


To read more or access our algorithms and calculators, please log in or register.